Replies to post #191735 on Biotech Values

[mcbio]

GBIM -60% PM on failure of phase-2 HBV trial of GS-4774, which is partnered with GILD

Glad I never seriously considered that one. ; )

[DewDiligence]

GBIM evaluating “strategic alternatives” consequent to failure in HBV program (#msg-114047018):

http://finance.yahoo.com/news/globeimmune-announces-evaluation-strategic-alternatives-103000915.html

[DewDiligence]

(GBIM)—GILD formally announced discontinuation of GS-4774 for HBV today.